Extended Data Table 6 Ad hoc analysis of confirmed tumor responsesa per RECIST v1.1 in patients with measurable disease

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  1. aDefined as responses with a second scan ≥4 weeks after the first documentation of response.
  2. bOne patient was missing a value for CLDN18.2 expression.
  3. cDefined as ≥75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  4. dDefined as ≥50% to <75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  5. Efficacy was assessed as an exploratory analysis in cohort 4 A + 4B.
  6. BOR, best overall response; CI, confidence interval; CLDN18, claudin 18; CLDN18.2, claudin 18 isoform 2; CR, complete response; DCR, disease control rate; IHC, immunohistochemistry; NE, not estimable; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.
Back to article page